Foghorn Therapeutics Inc. (FHTX)
4.11
-0.07 (1.67%)
Upcoming Events
Latest Headlines
Nuvation Bio (NUVB) Reiterated at Market Outperform by Citizens Amid Acquisition by GSK
June 10, 2026 5:19 AM - StreetInsider
Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
June 5, 2026 7:00 AM - StreetInsider
Form SCHEDULE 13G/A Foghorn Therapeutics Filed by: BIOTECHNOLOGY VALUE FUND L P
May 15, 2026 4:16 PM - SEC Filing
Form SCHEDULE 13G/A Foghorn Therapeutics Filed by: Flynn James E
May 14, 2026 6:21 PM - SEC Filing
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May
May 12, 2026 7:00 AM - Globe NewsWire
Foghorn Therapeutics Inc. (FHTX) Misses Q1 EPS by 1c
May 7, 2026 7:44 AM - StreetInsider
Form 10-Q Foghorn Therapeutics For: Mar 31
May 7, 2026 7:03 AM - SEC Filing
Form 8-K Foghorn Therapeutics For: May 07
May 7, 2026 7:02 AM - SEC Filing
Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update
May 7, 2026 7:00 AM - Globe NewsWire
Form SCHEDULE 13G/A Foghorn Therapeutics Filed by: FMR LLC
May 6, 2026 11:19 AM - SEC Filing
Form ARS Foghorn Therapeutics For: Dec 31
April 30, 2026 7:10 AM - SEC Filing
Form DEFA14A Foghorn Therapeutics
April 30, 2026 7:05 AM - SEC Filing
Form DEF 14A Foghorn Therapeutics For: Jun 24
April 30, 2026 7:01 AM - SEC Filing
Foghorn Therapeutics (FHTX) Reiterated at Buy by Stifel After AACR'26 Presentation
April 27, 2026 7:31 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Foghorn Therapeutics (FHTX)
April 22, 2026 6:41 AM - StreetInsider
Foghorn presents preclinical data for cancer drug candidates at AACR
April 21, 2026 4:05 PM - StreetInsider
Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
April 21, 2026 4:05 PM - StreetInsider
Form 8-K Foghorn Therapeutics For: Apr 21
April 21, 2026 4:03 PM - SEC Filing
Form 4 Foghorn Therapeutics For: Apr 09 Filed by: GOTTSCHALK ADRIAN
April 13, 2026 4:01 PM - SEC Filing
Foghorn Therapeutics to share preclinical cancer drug data at AACR meeting
April 9, 2026 7:01 AM - StreetInsider
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
April 9, 2026 7:00 AM - StreetInsider
Form S-8 Foghorn Therapeutics
March 26, 2026 4:03 PM - SEC Filing
Full Article List
